IAE classification for the manufacture of immunological medicines

The correct classification of an economic activity in the Business Activities Tax (IAE) is fundamental to avoid tax contingencies. Recently, the Directorate General of Taxes (DGT) has issued a criterion regarding the classification of companies dedicated to the production of immunological medicines for human use.

What the DGT has resolved

The query sought to determine whether the manufacture of products such as vaccines, toxins, sera, and allergens should be registered under heading 254.1, corresponding to the manufacture of basic pharmaceutical products, or under heading 254.2.

The DGT has resolved that this activity corresponds to heading 254.2 of the first section of the IAE Tariffs. The basis for this decision lies in the nature of the manufactured products: as they are medicines for immediate medicinal use that do not require a subsequent production process, they are classified as specialties and other pharmaceutical products, rather than basic products.

What this means for you

This criterion has a direct impact on companies dedicated to the production of immunological drugs. The distinction between a basic product and a pharmaceutical specialty is not merely terminological; it defines the heading in which the company must be registered for the tax.

If an entity operates under the heading for basic products (254.1) when its activity generates products for immediate medicinal use, it could be committing an error in its IAE registration. The criterion establishes that the capacity for direct use of the product is the determining factor for its correct categorization.

What should be done

Pharmaceutical sector companies that manufacture vaccines, sera, or allergens should verify that their IAE registration matches the nature of their final production. It is necessary to check whether the products resulting from their processes require additional transformations by third parties or if they are intended for immediate medicinal use. It is recommended to analyze the composition of the activity to ensure that the applied heading is the one required by current regulations.